Tresiba
Novo’s Tresiba lowers hypoglycaemia risk compared to insulin glargine in type 2 diabetes
September 20, 2019Medical Communications, Research and Development Novo Nordisk, Tresiba, diabetes, pharma
Novo Nordisk has unveiled new data for Tresiba (insulin degludec) at the 55th Annual Meeting of the European Association for …
Novo Nordisk unveils hard-hitting data for two of its diabetes therapies
December 5, 2017Manufacturing and Production, Research and Development Novo Nordisk, Tresiba, Xultophy, diabetes, pharma
Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and …
Novo Nordisk presents Tresiba data showing significantly lower hypoglycaemia rates
June 13, 2016Research and Development, Sales and Marketing Novo Nordisk, Tresiba
Novo Nordisk (CPH: NOVO-B) has presented new Phase IIIb data on Tresiba (insulin degludec) at the American Diabetes Association annual …
FDA committee unanimously recommends Novo Nordisk diabetes combo, IDegLira
May 25, 2016Research and Development, Sales and Marketing FDA, Novo Nordisk, Panel, Tresiba, Victoza, committee, ideglira, recommendation, staff
Novo Nordisk has announced that a US Food and Drug Administration (FDA) advisory committee has unanimously recommended IDegLira, a type-2 …
FDA approves Novo Nordisk’s diabetes drugs
September 28, 2015Sales and Marketing FDA, Novo Nordisk, Ryzodeg, Tresiba, diabetes, insulin
The FDA has approved two Novo Nordisk drugs, Tresiba and Ryzodeg, for the treatment of type 2 diabetes in adults.The …
Novo Nordisk pulls Tresiba in Germany after pricing row
July 6, 2015Manufacturing and Production, Sales and Marketing Drug pricing, Germany, Novo Nordisk, Reimbursement, Tresiba, market access
Novo Nordisk has discontinued its distribution of once-daily basal insulin Tresiba after pricing talks with the German body that represents …
FDA to look again at Novo Nordisk insulin submissions
April 8, 2015Research and Development, Sales and Marketing Novo Nordisk, Ryzodeg, Tresiba, diabetes, insulin degludec
Diabetes specialist firm Novo Nordisk has resubmitted its applications for two insulins to the FDA, along with new interim safety …
Novo resubmits FDA application for two diabetes drugs
March 27, 2015Sales and Marketing Danish, FDA, Novo Nordisk, Ryzodeg, Tresiba, diabetes
Novo Nordisk will re-submit an FDA application for its diabetes drugs Tresiba and Ryzodeg two years after their initial rejection …
Novo Nordisk to open $130 million diabetes labs
November 3, 2014Manufacturing and Production, Sales and Marketing Denmark, Måløv, Novo Nordisk, Tresiba, Victoza, diabetes
Novo Nordisk has invested $130 million in new diabetes laboratories as the company looks to focus more strongly on the …
FDA rejects Novo diabetes drugs
February 12, 2013Sales and Marketing FDA, Novo Nordisk, Ryzodeg, Tresiba
The FDA has knocked back two of Novo Nordisk’s diabetes drugs – just weeks after they were approved for use …
EU approval for Novo Nordisk diabetes drugs
January 24, 2013Sales and Marketing Novo Nordisk, Ryzodeg, Tresiba
Novo Nordisk is celebrating after European regulators approved two of its drugs for the treatment of adults with diabetes. The …
European green light for Novo’s Tresiba
October 24, 2012Sales and Marketing EMA, Novo Nordisk, Tresiba
The European Medicines Agency has given the go-ahead for Novo Nordisk’s Tresiba, a new basal analogue insulin to treat diabetes …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
